Antioxidant treatment strategies for hyperphenylalaninemia

Metabolic Brain Disease

Volumn 28, Issue 4, 2013, Pages 541-550

  Mazzola, Priscila Nicolao ^a   Karikas, George Albert ^b   Schulpis, Kleopatra H ^c   Dutra Filho, Carlos Severo ^a  

^a FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^b UNIVERSITY OF WEST ATTICA   (Greece)

^c AGHIA SOPHIA CHILDREN S HOSPITAL   (Greece)

Author keywords

Diet; Exercise; Hyperphenylalaninemia; Oxidative stress; Phenylketonuria; Supplementation

Indexed keywords

ALPHA TOCOPHEROL; ANTIOXIDANT; CARNITINE; CATALASE; COBALAMIN; GLUTATHIONE PEROXIDASE; MELATONIN; PHENYLALANINE; SELENIUM; SUPEROXIDE DISMUTASE; TETRAHYDROBIOPTERIN; THIOCTIC ACID; UBIDECARENONE; VITAMIN;

BIOCHEMISTRY; COGNITION; EARLY DIAGNOSIS; EXERCISE; GENETICS; HUMAN; HYPERPHENYLALANINEMIA; NONHUMAN; NUTRIENT; NUTRIENT CONTENT; OXIDATIVE STRESS; PHENYLKETONURIA; REVIEW; VITAMIN SUPPLEMENTATION;

ANIMALIA;

ANTIOXIDANTS; BRAIN; DIET; DIETARY SUPPLEMENTS; HUMANS; OXIDATIVE STRESS; PHENYLKETONURIAS;

EID: 84887218913     PISSN: 08857490     EISSN: 15737365     Source Type: Journal    
DOI: 10.1007/s11011-013-9414-2     Document Type: Review

References (110)

1. Agostoni C, Verduci E, Fiori L, Riva E, Giovannini M (2000) Breastfeeding rates among hyperphenylalaninemic infants. Acta Paediatr 89(3):366-367
2. Alves CR, Murai IH, Ramona P, Nicastro H, Bechara LR, Lancha AH Jr, Brum PC, Irigoyen MC, Gualano B (2012) No effect of creatine supplementation on oxidative stress and cardiovascular parameters in spontaneously hypertensive rats. J Int Soc Sports Nutr 9(1):13. doi: 10.1186/1550-2783-9-13
3. Amer J, Ghoti H, Rachmilewitz E, Koren A, Levin C, Fibach E (2006) Red blood cells, platelets and polymorphonuclear neutrophils of patients with sickle cell disease exhibit oxidative stress that can be ameliorated by antioxidants. Br J Haematol 132(1):108-113. doi: 10.1111/j.1365-2141.2005.05834.x
4. Anjema K, van Rijn M, Verkerk PH, Burgerhof JG, Heiner-Fokkema MR, van Spronsen FJ (2011) PKU: High plasma phenylalanine concentrations are associated with increased prevalence of mood swings. Mol Genet Metab. doi: 10.1016/j.ymgme.2011.05.017
5. Artuch R, Colome C, Sierra C, Brandi N, Lambruschini N, Campistol J, Ugarte D, Vilaseca MA (2004) A longitudinal study of antioxidant status in phenylketonuric patients. Clin Biochem 37(3):198-203. doi: 10.1016/j. clinbiochem.2003.10.017
6. Back SA, Kroenke CD, Sherman LS, Lawrence G, Gong X, Taber EN, Sonnen JA, Larson EB, Montine TJ (2011) White matter lesions defined by diffusion tensor imaging in older adults. Ann Neurol 70(3):465-476. doi: 10.1002/ana.22484
7. Banta-Wright SA, Shelton KC, Lowe ND, Knafl KA, Houck GM (2012) Breast-feeding success among infants with phenylketonuria. J Pediatr Nurs 27(4):319-327. doi: 10.1016/j.pedn.2011.03.015
8. Baud O, Greene AE, Li J, Wang H, Volpe JJ, Rosenberg PA (2004) Glutathione peroxidase-catalase cooperativity is required for resistance to hydrogen peroxide by mature rat oligodendrocytes. J Neurosci 24(7):1531-1540. doi: 10.1523/JNEUROSCI.3989-03.2004
9. Bender A, Beckers J, Schneider I, Holter SM, Haack T, Ruthsatz T, Vogt-Weisenhorn DM, Becker L, Genius J, Rujescu D, Irmler M, Mijalski T, Mader M, Quintanilla-Martinez L, Fuchs H, Gailus-Durner V, de Angelis MH, Wurst W, Schmidt J, Klopstock T (2008) Creatine improves health and survival of mice. Neurobiol Aging 29(9):1404-1411. doi: 10.1016/j.neurobiolaging.2007.03.001
10. Berger MM (2005) Can oxidative damage be treated nutritionally? Clin Nutr 24:172-183. doi: 10.1016/j.clnu.2004.10.003
11. Berti SL, Nasi GM, Garcia C, de Castro FL, Nunes ML, Rojas DB, Moraes TB, Dutra-Filho CS, Wannmacher CM (2012) Pyruvate and creatine prevent oxidative stress and behavioral alterations caused by phenylalanine administration into hippocampus of rats. Metab Brain Dis. doi: 10.1007/s11011-011-9271-9
12. Blau N, Belanger-Quintana A, Demirkol M, Feillet F, Giovannini M, MacDonald A, Trefz FK, van Spronsen F (2010) Management of phenylketonuria in Europe: survey results from 19 countries. Mol Genet Metab 99(2):109-115. doi: 10.1016/j.ymgme.2009.09.005
13. Blau N, Belanger-Quintana A, Demirkol M, Feillet F, Giovannini M, MacDonald A, Trefz FK, van Spronsen FJ (2009) Optimizing the use of sapropterin (BH(4)) in the management of phenylketonuria. Mol Genet Metab 96(4):158-163. doi: 10.1016/j.ymgme.2009.01.002
14. Boskovic M, Vovk T, Kores Plesnicar B, Grabnar I (2011) Oxidative stress in schizophrenia. Curr Neuropharmacol 9(2):301-312. doi: 10.2174/ 157015911795596595
15. Carocho M, Ferreira IC (2013) A review on antioxidants, prooxidants and related controversy: natural and synthetic compounds, screening and analysis methodologies and future perspectives. Food Chem Toxicol 51:15-25. doi: 10.1016/j.fct.2012.09.021
16. Cleary MA, Walter JH, Wraith JE, White F, Tyler K, Jenkins JP (1995) Magnetic resonance imaging in phenylketonuria: reversal of cerebral white matter change. J Pediatr 127(2):251-255
17. Colome C, Artuch R, Vilaseca MA, Sierra C, Brandi N, Lambruschini N, Cambra FJ, Campistol J (2003) Lipophilic antioxidants in patients with phenylketonuria. Am J Clin Nutr 77(1):185-188
18. Cotugno G, Nicolo R, Cappelletti S, Goffredo B, Dionisi Vici C, Di Ciommo V (2011) Adherence to diet and quality of life in patients with phenylketonuria. Acta Paediatr 100(8):1144-1149. doi: 10.1111/j.1651-2227.2011. 02227.x
19. Cunnington C, Channon KM (2010) Tetrahydrobiopterin: pleiotropic roles in cardiovascular pathophysiology. Heart 96(23):1872-1877. doi: 10.1136/hrt.2009.180430
20. de Diego-Otero Y, Romero-Zerbo Y, el Bekay R, Decara J, Sanchez L, Rodriguez-de Fonseca F, del Arco-Herrera I (2009) Alpha-tocopherol protects against oxidative stress in the fragile X knockout mouse: an experimental therapeutic approach for the Fmr1 deficiency. Neuropsychopharmacology 34(4):1011-1026. doi: 10.1038/npp.2008.152
21. de Groot MJ, Hoeksma M, Blau N, Reijngoud DJ, van Spronsen FJ (2010) Pathogenesis of cognitive dysfunction in phenylketonuria: review of hypotheses. Mol Genet Metab 99(Suppl 1):S86-S89. doi: 10.1016/j.ymgme.2009.10.016
22. Dean OM, van den Buuse M, Berk M, Copolov DL, Mavros C, Bush AI (2011) N-acetyl cysteine restores brain glutathione loss in combined 2-cyclohexene-1-one and d-amphetamine-treated rats: relevance to schizophrenia and bipolar disorder. Neurosci Lett 499(3):149-153. doi: 10.1016/j.neulet.2011. 05.027
23. Dibble LE, Addison O, Papa E (2009) The effects of exercise on balance in persons with Parkinson's disease: a systematic review across the disability spectrum. J Neurol Phys Ther 33(1):14-26. doi: 10.1097/NPT.0b013e3181990fcc
24. Ding Z, Harding CO, Thony B (2004) State-of-the-art 2003 on PKU gene therapy. Mol Genet Metab 81(1):3-8
25. Dominguez-Rodriguez A, Abreu-Gonzalez P, Avanzas P (2012) The role of melatonin in acute myocardial infarction. Front Biosci 17:2433-2441
26. Feillet F, Agostoni C (2010) Nutritional issues in treating phenylketonuria. J Inherit Metab Dis 33(6):659-664. doi: 10.1007/s10545-010- 9043-4
27. Fernandes CG, Leipnitz G, Seminotti B, Amaral AU, Zanatta A, Vargas CR, Dutra Filho CS, Wajner M (2010) Experimental evidence that phenylalanine provokes oxidative stress in hippocampus and cerebral cortex of developing rats. Cell Mol Neurobiol 30(2):317-326. doi: 10.1007/s10571-009-9455-6
28. Frayn KN (2010) Fat as a fuel: emerging understanding of the adipose tissue-skeletal muscle axis. Acta Physiol (Oxf) 199(4):509-518. doi: 10.1111/j.1748-1716.2010.02128.x
29. Gassio R, Artuch R, Vilaseca MA, Fuste E, Colome R, Campistol J (2008) Cognitive functions and the antioxidant system in phenylketonuric patients. Neuropsychology 22(4):426-431. doi: 10.1037/0894-4105.22.4.426
30. Gokmen-Ozel H, MacDonald A, Daly A, Hall K, Ryder L, Chakrapani A (2009) Long-term efficacy of 'ready-to-drink' protein substitute in phenylketonuria. J Hum Nutr Diet 22(5):422-427. doi: 10.1111/j.1365-277X.2009.00998.x
31. Guimarães-Ferreira L, Pinheiro CH, F. G-R, Vitzel KF, Nachbar RT, Curi R, Nunes MT (2012) Short-term creatine supplementation decreases reactive oxygen species content with no changes in expression and activity of antioxidant enzymes in skeletal muscle. Eur J Appl Physiol [Epub ahead of print]
32. Gulcin I (2006) Antioxidant and antiradical activities of L-carnitine. Life Sci 78(8):803-811. doi: 10.1016/j.lfs.2005.05.103
33. Guldberg P, Henriksen KF, Sipila I, Guttler F, de la Chapelle A (1995) Phenylketonuria in a low incidence population: molecular characterisation of mutations in Finland. J Med Genet 32(12):976-978
34. Halliwell B (2006) Oxidative stress and neurodegeneration: where are we now? J Neurochem 97:1634-1658. doi: 10.1111/j.1471-4159.2006.03907.x
35. Halliwell B (2011) Free radicals and antioxidants - quo vadis? Trends Pharmacol Sci 32:125-130. doi: 10.1016/j.tips.2010.12.002
36. Halliwell B, Gutteridge JM (2007) Free radicals in biology and medicine, 4th edn. Oxford University Press, New York
37. Hanley WB (2004) Adult phenylketonuria. Am J Med 117(8):590-595. doi: 10.1016/j.amjmed.2004.03.042
38. Hufton SE, Jennings IG, Cotton RG (1995) Structure and function of the aromatic amino acid hydroxylases. Biochem J 311(Pt 2):353-366
39. Hyland K (2007) Inherited disorders affecting dopamine and serotonin: critical neurotransmitters derived from aromatic amino acids. J Nutr 137(6 Suppl 1):1568S-1572S, discussion 1573S-1575S
40. Jaffe EK, Stith L, Lawrence SH, Andrake M, Dunbrack RL Jr (2013) A new model for allosteric regulation of phenylalanine hydroxylase: implications for disease and therapeutics. Arch Biochem Biophys 530:73-82. doi: 10.1016/j.abb.2012.12.017
41. Jans JJ, de Sain-van der Velden MG, van Hasselt PM, van den Hurk DT, Vaz FM, Visser G, Verhoeven-Duif NM (2013) Supplementation with a powdered blend of PUFAs normalizes DHA and AA levels in patients with PKU. Mol Genet Metab. doi: 10.1016/j.ymgme.2013.03.006
42. Kanufre VC, Starling AL, Leao E, Aguiar MJ, Santos JS, Soares RD, Silveira AM (2007) Breastfeeding in the treatment of children with phenylketonuria. J Pediatr (Rio J) 83(5):447-452. doi: 10.2223/JPED.1672
43. Karikas GA, Kriebardis A, Samara I, Schulpis K, Papachristodoulou M, Fytou-Pallikari A (2006) Serum homocysteine levels and paraoxonase 1 activity in preschool aged children in Greece. Clin Chem Lab Med 44(5):623-627. doi: 10.1515/CCLM.2006.110
44. Kennedy G, Spence VA, McLaren M, Hill A, Underwood C, Belch JJ (2005) Oxidative stress levels are raised in chronic fatigue syndrome and are associated with clinical symptoms. Free Radic Biol Med 39(5):584-589. doi: 10.1016/j.freeradbiomed.2005.04.020
45. Knudsen GM, Hasselbalch S, Toft PB, Christensen E, Paulson OB, Lou H (1995) Blood-brain barrier transport of amino acids in healthy controls and in patients with phenylketonuria. J Inherit Metab Dis 18(6):653-664
46. Kohli S, Saxena R, Thomas E, Rao P, Verma IC (2005) Prenatal diagnosis of phenylketonuria. Indian J Med Res 122(5):400-403
47. Koletzko B, Beblo S, Demmelmair H, Hanebutt FL (2009) Omega-3 LC-PUFA supply and neurological outcomes in children with phenylketonuria (PKU). J Pediatr Gastroenterol Nutr 48(Suppl 1):S2-S7. doi: 10.1097/MPG.0b013e3181977399
48. Konecki DS, Wang Y, Trefz FK, Lichter-Konecki U, Woo SL (1992) Structural characterization of the 5′ regions of the human phenylalanine hydroxylase gene. Biochemistry 31(35):8363-8368
49. Kvetnansky R, Sabban EL, Palkovits M (2009) Catecholaminergic systems in stress: structural and molecular genetic approaches. Physiol Rev 89(2):535-606. doi: 10.1152/physrev.00042.2006
50. Laboratory D (2003) PAH: Phenylalanine hydroxylase locus knowledgebase. http://www.pahdb.mcgill.ca/. Accessed 19 January 2013
51. Lavoie SM, Harding CO, Gillingham MB (2009) Normal fatty acid concentrations in young children with Phenylketonuria (Pku). Top Clin Nutr 24:333-340. doi: 10.1097/TIN.0b013e3181c621fa
52. Leuret O, Barth M, Kuster A, Eyer D, de Parscau L, Odent S, Gilbert-Dussardier B, Feillet F, Labarthe F (2012) Efficacy and safety of BH4 before the age of 4 years in patients with mild phenylketonuria. J Inherit Metab Dis. doi: 10.1007/s10545-012-9464-3
53. Li Z, Boules M, Williams K, Gordillo A, Li S, Richelson E (2010) Similarities in the behavior and molecular deficits in the frontal cortex between the neurotensin receptor subtype 1 knockout mice and chronic phencyclidine-treated mice: relevance to schizophrenia. Neurobiol Dis 40(2):467-477. doi: 10.1016/j.nbd.2010.07.011
54. Lidsky AS, Law ML, Morse HG, Kao FT, Rabin M, Ruddle FH, Woo SL (1985) Regional mapping of the phenylalanine hydroxylase gene and the phenylketonuria locus in the human genome. Proc Natl Acad Sci U S A 82(18):6221-6225
55. Lindegren ML, Krishnaswami S, Fonnesbeck C, Reimschisel T, Fisher J, Jackson K, Shields T, Sathe NA, McPheeters ML (2012). doi:NBK91350 [bookaccession]
56. Lu J, Berndt C, Holmgren A (2009) Metabolism of selenium compounds catalyzed by the mammalian selenoprotein thioredoxin reductase. Biochim Biophys Acta 1790(11):1513-1519. doi: 10.1016/j.bbagen.2009.04.013
57. Lu L, Gu X, Li D, Liang L, Zhao Z, Gao J (2011) Mechanisms regulating superoxide generation in experimental models of phenylketonuria: an essential role of NADPH oxidase. Mol Genet Metab 104(3):241-248. doi: 10.1016/j.ymgme. 2011.05.012
58. Mazzola PN, Terra M, Rosa AP, Mescka CP, Moraes TB, Piccoli B, Jacques CE, Dalazen G, Cortes MX, Coelho J, Dutra-Filho CS (2011) Regular exercise prevents oxidative stress in the brain of hyperphenylalaninemic rats. Metab Brain Dis 26(4):291-297. doi: 10.1007/s11011-011-9264-8
59. Mikoluc B, Motkowski R, Karpinska J, Amilkiewicz J, Didycz B, Gizewska M, Lange A, Milanowski A, Nowacka M, Sands D, Schneiberg B, Starostecka E, Wojcicka-Bartlomiejczyk I, Piotrowska-Jastrzebska J (2012) Impact of lipophilic antioxidants and level of antibodies against oxidized low-density lipoprotein in Polish children with phenylketonuria. Antioxid Redox Signal 16(2):179-182. doi: 10.1089/ars.2011.4163
60. Moens AL, Kass DA (2006) Tetrahydrobiopterin and cardiovascular disease. Arterioscler Thromb Vasc Biol 26(11):2439-2444. doi: 10.1161/01.ATV.0000243924. 00970.cb
61. Moens AL, Kietadisorn R, Lin JY, Kass D (2011) Targeting endothelial and myocardial dysfunction with tetrahydrobiopterin. J Mol Cell Cardiol 51(4):559-563. doi: 10.1016/j.yjmcc.2011.03.009
62. Moraes TB, Jacques CE, Rosa AP, Dalazen GR, Terra M, Coelho JG, Dutra-Filho CS (2013) Role of catalase and superoxide dismutase activities on oxidative stress in the brain of a phenylketonuria animal model and the effect of lipoic Acid. Cell Mol Neurobiol 33(2):253-260. doi: 10.1007/s10571-012-9892-5
63. Moraes TB, Zanin F, da Rosa A, de Oliveira A, Coelho J, Petrillo F, Wajner M, Dutra-Filho CS (2010) Lipoic acid prevents oxidative stress in vitro and in vivo by an acute hyperphenylalaninemia chemically-induced in rat brain. J Neurol Sci 292(1-2):89-95. doi: 10.1016/j.jns.2010.01.016
64. Mutze U, Beblo S, Kortz L, Matthies C, Koletzko B, Bruegel M, Rohde C, Thiery J, Kiess W, Ceglarek U (2012) Metabolomics of dietary Fatty Acid restriction in patients with phenylketonuria. PLoS One 7(8):e43021. doi: 10.1371/journal.pone.0043021
65. Nalin T, Perry ID, Sitta A, Vargas CR, Saraiva-Pereira ML, Giugliani R, Blau N, Schwartz IV (2011) Optimized loading test to evaluate responsiveness to tetrahydrobiopterin (BH4) in Brazilian patients with phenylalanine hydroxylase deficiency. Mol Genet Metab 104(Suppl):S80-S85. doi: 10.1016/j.ymgme.2011.09.019
66. Okano Y, Hase Y, Lee DH, Furuyama J, Shintaku H, Oura T, Isshiki G (1992) Frequency and distribution of phenylketonuric mutations in Orientals. Hum Mutat 1(3):216-220. doi: 10.1002/humu.1380010307
67. Papp LV, Holmgren A, Khanna KK (2010) Selenium and selenoproteins in health and disease. Antioxid Redox Signal 12(7):793-795. doi: 10.1089/ars.2009.2973
68. Pohorecky LA, Blakley GG, Kubovcakova L, Krizanova O, Patterson-Buckendahl P, Kvetnansky R (2004) Social hierarchy affects gene expression for catecholamine biosynthetic enzymes in rat adrenal glands. Neuroendocrinology 80(1):42-51. doi: 10.1159/000080664
69. Quirk ME, Dobrowolski SF, Nelson BE, Coffee B, Singh RH (2012) Utility of phenylalanine hydroxylase genotype for tetrahydrobiopterin responsiveness classification in patients with phenylketonuria. Mol Genet Metab. doi: 10.1016/j.ymgme.2012.07.008
70. Ramond A, Godin-Ribuot D, Ribuot C, Totoson P, Koritchneva I, Cachot S, Levy P, Joyeux-Faure M (2011) Oxidative stress mediates cardiac infarction aggravation induced by intermittent hypoxia. Fundam Clin Pharmacol. doi: 10.1111/j.1472-8206.2011.01015.x
71. Rech VC, Feksa LR, Dutra-Filho CS, Wyse AT, Wajner M, Wannmacher CM (2002) Inhibition of the mitochondrial respiratory chain by phenylalanine in rat cerebral cortex. Neurochem Res 27(5):353-357
72. Ribas GS, Sitta A, Wajner M, Vargas CR (2011) Oxidative stress in phenylketonuria: what is the evidence? Cell Mol Neurobiol 31(5):653-662. doi: 10.1007/s10571-011-9693-2
73. Richardson SC, Aspbury RA, Fisher MJ (1993) The role of reversible phosphorylation in the hormonal control of phenylalanine hydroxylase in isolated rat proximal kidney tubules. Biochem J 292(Pt 2):419-424
74. Robinson M, White FJ, Cleary MA, Wraith E, Lam WK, Walter JH (2000) Increased risk of vitamin B12 deficiency in patients with phenylketonuria on an unrestricted or relaxed diet. J Pediatr 136(4):545-547
75. Rocha JC, Martins MJ (2012) Oxidative stress in phenylketonuria: future directions. J Inherit Metab Dis 35(3):381-398. doi: 10.1007/s10545-011-9417-2
76. Samuel S, Kathirvel R, Jayavelu T, Chinnakkannu P (2005) Protein oxidative damage in arsenic induced rat brain: influence of DL-alpha-lipoic acid. Toxicol Lett 155(1):27-34. doi: 10.1016/j.toxlet.2004.08.001
77. Sanayama Y, Nagasaka H, Takayanagi M, Ohura T, Sakamoto O, Ito T, Ishige-Wada M, Usui H, Yoshino M, Ohtake A, Yorifuji T, Tsukahara H, Hirayama S, Miida T, Fukui M, Okano Y (2011) Experimental evidence that phenylalanine is strongly associated to oxidative stress in adolescents and adults with phenylketonuria. Mol Genet Metab 103(3):220-225. doi: 10.1016/j.ymgme.2011.03. 019
78. Sarkissian CN, Gamez A, Scriver CR (2009) What we know that could influence future treatment of phenylketonuria. J Inherit Metab Dis 32(1):3-9. doi: 10.1007/s10545-008-0917-7
79. Sarkissian CN, Shao Z, Blain F, Peevers R, Su H, Heft R, Chang TM, Scriver CR (1999) A different approach to treatment of phenylketonuria: phenylalanine degradation with recombinant phenylalanine ammonia lyase. Proc Natl Acad Sci U S A 96(5):2339-2344
80. Schulpis KH, Kalogerakou M, Gioni V, Papastamataki M, Papassotiriou I (2011) Glutamine, ornithine, citrulline and arginine levels in children with phenylketonuria: The diet effect. Clin Biochem 44(10-11):821-825. doi: 10.1016/j.clinbiochem.2011.05.002
81. Schulpis KH, Karikas GA, Papakonstantinou E (2002) Homocysteine and other vascular risk factors in patients with phenylketonuria on a diet. Acta Paediatr 91(8):905-909
82. Schulpis KH, Papassotiriou I, Vounatsou M, Karikas GA, Tsakiris S, Chrousos GP (2004) Morning preprandial plasma ghrelin and catecholamine concentrations in patients with phenylketonuria and normal controls: evidence for catecholamine-mediated ghrelin regulation. J Clin Endocrinol Metab 89(8):3983-3987. doi: 10.1210/jc.2004-0311
83. Schulpis KH, Papastamataki M, Stamou H, Papassotiriou I, Margeli A (2010) The effect of diet on total antioxidant status, ceruloplasmin, transferrin and ferritin serum levels in phenylketonuric children. Acta Paediatr 99(10):1565-1570. doi: 10.1111/j.1651-2227.2010.01890.x
84. Schulpis KH, Tsakiris S, Karikas GA, Moukas M, Behrakis P (2003) Effect of diet on plasma total antioxidant status in phenylketonuric patients. Eur J Clin Nutr 57(2):383-387. doi: 10.1038/sj.ejcn.1601529
85. Schulpis KH, Tsakiris S, Traeger-Synodinos J, Papassotiriou I (2005) Low total antioxidant status is implicated with high 8-hydroxy-2-deoxyguanosine serum concentrations in phenylketonuria. Clin Biochem 38(3):239-242. doi: 10.1016/j.clinbiochem.2004.11.006
86. Scriver CR, Kaufman S (eds) (2001) Hyperphenylalaninemia: Phenylalnine Hydroxylase deficiency, vol II. The metabolic & molecular inherited disease. McGraw-Hill, New York
87. Shefer S, Tint GS, Jean-Guillaume D, Daikhin E, Kendler A, Nguyen LB, Yudkoff M, Dyer CA (2000) Is there a relationship between 3-hydroxy-3- methylglutaryl coenzyme a reductase activity and forebrain pathology in the PKU mouse? J Neurosci Res 61(5):549-563
88. Simonyi A, He Y, Sheng W, Sun AY, Wood WG, Weisman GA, Sun GY (2010) Targeting NADPH oxidase and phospholipases A2 in Alzheimer's disease. Mol Neurobiol 41(2-3):73-86. doi: 10.1007/s12035-010-8107-7
89. Singh N, Dhalla AK, Seneviratne C, Singal PK (1995) Oxidative stress and heart failure. Mol Cell Biochem 147(1-2):77-81
90. Sitta A, Barschak AG, Deon M, Barden AT, Biancini GB, Vargas PR, de Souza CF, Netto C, Wajner M, Vargas CR (2009a) Effect of short- and long-term exposition to high phenylalanine blood levels on oxidative damage in phenylketonuric patients. Int J Dev Neurosci 27(3):243-247. doi: 10.1016/j.ijdevneu.2009.01.001
91. Sitta A, Barschak AG, Deon M, de Mari JF, Barden AT, Vanzin CS, Biancini GB, Schwartz IV, Wajner M, Vargas CR (2009b) L-carnitine blood levels and oxidative stress in treated phenylketonuric patients. Cell Mol Neurobiol 29(2):211-218. doi: 10.1007/s10571-008-9313-y
92. Sitta A, Barschak AG, Deon M, Terroso T, Pires R, Giugliani R, Dutra-Filho CS, Wajner M, Vargas CR (2006) Investigation of oxidative stress parameters in treated phenylketonuric patients. Metab Brain Dis 21(4):287-296. doi: 10.1007/s11011-006-9035-0
93. Sitta A, Vanzin CS, Biancini GB, Manfredini V, de Oliveira AB, Wayhs CA, Ribas GO, Giugliani L, Schwartz IV, Bohrer D, Garcia SC, Wajner M, Vargas CR (2011) Evidence that L-carnitine and selenium supplementation reduces oxidative stress in phenylketonuric patients. Cell Mol Neurobiol 31(3):429-436. doi: 10.1007/s10571-010-9636-3
94. Sterl E, Paul K, Paschke E, Zschocke J, Brunner-Krainz M, Windisch E, Konstantopoulou V, Moslinger D, Karall D, Scholl-Burgi S, Sperl W, Lagler F, Plecko B (2012) Prevalence of tetrahydrobiopterine (BH4)-responsive alleles among Austrian patients with PAH deficiency: comprehensive results from molecular analysis in 147 patients. J Inherit Metab Dis. doi: 10.1007/s10545-012-9485-y
95. Sun GY, Horrocks LA, Farooqui AA (2007) The roles of NADPH oxidase and phospholipases A2 in oxidative and inflammatory responses in neurodegenerative diseases. J Neurochem 103(1):1-16. doi: 10.1111/j.1471-4159.2007.04670.x
96. Surtees R, Blau N (2000) The neurochemistry of phenylketonuria. Eur J Pediatr 159(Suppl 2):S109-S113
97. Teixeira VH, Valente HF, Casal SI, Marques AF, Moreira PA (2009) Antioxidants do not prevent postexercise peroxidation and may delay muscle recovery. Med Sci Sports Exerc 41(9):1752-1760. doi: 10.1249/MSS. 0b013e31819fe8e3
98. Thiele AG, Weigel JF, Ziesch B, Rohde C, Mutze U, Ceglarek U, Thiery J, Muller AS, Kiess W, Beblo S (2013) Nutritional changes and micronutrient supply in patients with Phenylketonuria under therapy with Tetrahydrobiopterin (BH(4)). JIMD Rep 9:31-40. doi: 10.1007/8904-2012-176
99. Thompson AJ, Tillotson S, Smith I, Kendall B, Moore SG, Brenton DP (1993) Brain MRI changes in phenylketonuria. Associations with dietary status Brain 116(Pt 4):811-821
100. Tsakiris S, Karikas GA, Parthimos T, Tsakiris T, Bakogiannis C, Schulpis KH (2009) Alpha-tocopherol supplementation prevents the exercise-induced reduction of serum paraoxonase 1/arylesterase activities in healthy individuals. Eur J Clin Nutr 63(2):215-221. doi: 10.1038/sj.ejcn.1602918
101. Um HS, Kang EB, Leem YH, Cho IH, Yang CH, Chae KR, Hwang DY, Cho JY (2008) Exercise training acts as a therapeutic strategy for reduction of the pathogenic phenotypes for Alzheimer's disease in an NSE/APPsw-transgenic model. Int J Mol Med 22(4):529-539
102. Utz JR, Lorentz CP, Markowitz D, Rudser KD, Diethelm-Okita B, Erickson D, Whitley CB (2012) START, a double blind, placebo-controlled pharmacogenetic test of responsiveness to sapropterin dihydrochloride in phenylketonuria patients. Mol Genet Metab 105(2):193-197. doi: 10.1016/j.ymgme.2011.10.014
103. Vajro P, Strisciuglio P, Houssin D, Huault G, Laurent J, Alvarez F, Bernard O (1993) Correction of phenylketonuria after liver transplantation in a child with cirrhosis. N Engl J Med 329(5):363. doi: 10.1056/NEJM199307293290517
104. Valko M, Leibfritz D, Moncol J, Cronin MT, Mazur M, Telser J (2007) Free radicals and antioxidants in normal physiological functions and human disease. Int J Biochem Cell Biol 39(1):44-84. doi: 10.1016/j.biocel.2006.07.001
105. van Spronsen FJ, Enns GM (2010) Future treatment strategies in phenylketonuria. Mol Genet Metab 99(Suppl 1):S90-S95. doi: 10.1016/j.ymgme.2009. 10.008
106. Vargas CR, Wajner M, Sitta A (2011) Oxidative stress in phenylketonuric patients. Mol Genet Metab 104(Suppl):S97-S99. doi: 10.1016/j.ymgme.2011.07.010
107. Vilaseca MA, Lambruschini N, Gomez-Lopez L, Gutierrez A, Fuste E, Gassio R, Artuch R, Campistol J (2010) Quality of dietary control in phenylketonuric patients and its relationship with general intelligence. Nutr Hosp 25(1):60-66
108. Walter JH, White FJ, Hall SK, MacDonald A, Rylance G, Boneh A, Francis DE, Shortland GJ, Schmidt M, Vail A (2002) How practical are recommendations for dietary control in phenylketonuria? Lancet 360(9326):55-57
109. Williams RA, Mamotte CD, Burnett JR (2008) Phenylketonuria: an inborn error of phenylalanine metabolism. Clin Biochem Rev 29(1):31-41
110. Zimmermann M, Jacobs P, Fingerhut R, Torresani T, Thony B, Blau N, Baumgartner MR, Rohrbach M (2012) Positive effect of a simplified diet on blood phenylalanine control in different phenylketonuria variants, characterized by newborn BH4 loading test and PAH analysis. Mol Genet Metab 106(3):264-268. doi: 10.1016/j.ymgme.2012.04.016